November 4, 2020 — SenseTime, an artificial intelligence (AI) company, announced its AI-empowered software solution, SenseCare-Lung Pro, has been awarded the CE mark to meet the safety and performance requirements demanded in the European Economic Area (EEA). The software enables faster and more automated diagnosis of lung diseases including COVID-19 infections based on CT image analysis.
The CE certification of SenseCare-Lung Pro ensures that the software can be commercialised in the EU market under the European Union Medical Device Regulation (MDR), a new regulation issued in response to the development of the medical device industry with higher requirements for the clinical evaluation and product testing before the device is approved for use in the market. The milestone demonstrates the solution's ability to analyze lung diseases safely and effectively.
Based on SenseTime's deep learning technologies, SenseCare-Lung Pro software improves the efficiency and accuracy of the diagnostic procedures for doctors in identifying lung cancers and pneumonia. Its AI capabilities mean it can automatically detect abnormalities of lung nodules and pneumonia, like COVID-19. It provides comprehensive analysis such as lesion classification, risk evaluation, quantification, and general structured reports.
"This is a significant milestone for SenseTime in our strategy to bring SenseCare-Lung Pro to international markets and support doctors in the diagnosis of critical lung diseases. The software has been further upgraded to detect suspect cases of COVID-19 during the pandemic to ease the strain on medical resources in Beijing, Shanghai, Tianjin and a dozen other cities. SenseTime will continue its extensive research activity to develop the highest quality and standards of AI products to empower the healthcare sector for the global community," said Zhang Shaoting, M.D., Vice President and Deputy Head of Research at SenseTime.
"In line with Indonesia's efforts to manage COVID-19, we identified a strong need for the SenseCare-Lung Pro to address pressing healthcare issues and support medical professionals in the early detection of the disease. Looking beyond the pandemic, Indonesia recently unveiled its 25-year national strategy for developing AI technologies with healthcare as a key thrust. We believe the SenseCare-Lung Pro will be a good solution in facilitating medical professionals in the early detection of respiratory diseases including COVID-19. SenseTime is committed to furthering this spirit of innovation to develop cutting-edge AI-powered health diagnostic solutions," said Martin Huang, Managing Director of SenseTime International Pte. Ltd.
SenseCare-Lung Pro is one of several applications in SenseTime's SenseCare Smart Health Platform – an AI-powered platform which offers an array of healthcare applications for over 13 organs and body parts, covering chest, cardiovascular, liver, pathology, orthopedics and radiotherapy. It can assist doctors throughout the clinical process, from diagnosis, 3-D surgery planning to rehabilitation tracking to meet the demands of various departments including radiology, pathology, cardiology, orthopedic, surgery, radiotherapy, etc.
For more information: www.sensetime.com
March 26, 2026 
